Protara Announces Closing of $100 Million Public Offering

TARA 12.11.2024

Full Press ReleaseSEC FilingsOur TARA Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Protara Highlights Recent Updates and Anticipated 2025 Milestones
  • 01.08.2025 - Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

NEW YORK,Dec. 11, 2024(GLOBE NEWSWIRE) --Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price of$6.25per share and pre-funded warrants to purchase 2,325,372 shares of common stock at a price of$6.249per pre-funded warrant, which represents the per share price for the common stock less the$0.001per share exercise price for each such pre-funded warrant. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 2,402,305 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately$100 millionbefore deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters’ option to purchase additional shares and the exercise of any pre-funded warrants. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.

TD Cowen, Cantor,LifeSci Capital,Oppenheimer & Co.and Scotiabank acted as joint book-running managers of the offering.

The shares of common stock and the pre-funded warrants were issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275290) that was declared effective onNovember 14, 2023by theU.S. Securities and Exchange Commission. The offering was made only by means of a prospectus supplement and the accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from the offices ofTD Securities (USA) LLC,1 Vanderbilt Avenue,New York, New York10017, by email atTD.ECM_Prospectus@tdsecurities.comor by telephone at (855) 495-9846;Cantor Fitzgerald & Co.,110 East 59th Street, 6th Floor,New York, New York10022, Attention: Capital Markets, or by email atprospectus@cantor.com; orLifeSci Capital LLC,1700 Broadway, 40th Floor,New York, New York10019, or by email atcompliance@lifescicapital.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Forward-lookingStatements

Statements contained in this press release regarding matters that are not historical facts are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the expected use of proceeds therefrom, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including Protara’s expectations related to the use of proceeds from the offering. Additional important factors to be considered in connection with forward-looking statements, including additional risks and uncertainties, are described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with theSecurities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:Justine O'MalleyProtara TherapeuticsJustine.OMalley@protaratx.com646-817-2836

Primary Logo

Source: Protara Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com